{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T08:05:35Z","timestamp":1779696335487,"version":"3.53.1"},"reference-count":27,"publisher":"Scientific Scholar","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Anaplastic thyroid carcinoma (ATC) is the most aggressive thyroid cancer and there is no established treatment that works well. The study was conducted to see prostate-specific membrane antigen (PSMA) expression in ATC as a stepping stone to study its role in potential theranostics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Pathologically proven ATC patients were prospectively included in this study. Ga-68-PSMA positron emission tomography\/computed tomography (PET\/CT) was done to look for PSMA expression in local and distant sites 45-60 mins after injecting 2-3mCi of tracer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Twenty patients were enrolled in this study. Nodal metastases were seen in all patients, while distant metastases were seen in 17\/20. The mean SUV\n                      <jats:sub>max<\/jats:sub>\n                      of primary lesion was 6.72 \u00b1 4.6. Mean SUVmax of node and lung lesions was 5.7 \u00b1 5.6 and 2.9 \u00b1 1.98, respectively. Mean SUV\n                      <jats:sub>max<\/jats:sub>\n                      of liver, mediastinum, and parotid gland was 5.95 \u00b1 3.03, 1.54 \u00b1 0.68, and 9.03 \u00b1 3.75, respectively. Mean Tumor to background ratio (liver = TBRl; mediastinum = TBRm; parotid = TBRp) were 1.21, 4.49 and 0.78, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>ATC showed variable PSMA expression on Ga-68-PSMA-PET\/CT and this attribute may be potentially useful in ATC theranostics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijnm.ijnm_21_22","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:52:18Z","timestamp":1669942338000},"page":"310-317","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Ga-68 Prostate-Specific Membrane Antigen-HBED-CC Positron Emission Tomography\/Computed Tomography in Anaplastic Thyroid Carcinoma"],"prefix":"10.25259","volume":"37","author":[{"given":"T. Kishan","family":"Subudhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishikant Avinash","family":"Damle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetanjali","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavi","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekhar","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipra","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","reference":[{"key":"R1-3-20240902","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.wjorl.2018.05.006","article-title":"Is the incidence of anaplastic thyroid cancer increasing: A population based epidemiology study","volume":"5","author":"Janz","year":"2019","journal-title":"World J Otorhinolaryngol Head Neck Surg"},{"key":"R2-3-20240902","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1067\/msy.2001.118266","article-title":"Anaplastic thyroid carcinoma: A 50-year experience at a single institution","volume":"130","author":"McIver","year":"2001","journal-title":"Surgery"},{"key":"R3-3-20240902","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/hed.20578","article-title":"Prognostic factors for Korean patients with anaplastic thyroid carcinoma","volume":"29","author":"Kim","year":"2007","journal-title":"Head Neck"},{"key":"R4-3-20240902","first-page":"956","article-title":"Anaplastic thyroid carcinoma: Risk factors and outcome","volume":"110","author":"Demeter","year":"1991","journal-title":"Surgery"},{"key":"R7-3-20240902","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1089\/thy.2012.0302","article-title":"American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer","volume":"22","author":"Smallridge","year":"2012","journal-title":"Thyroid"},{"key":"R8-3-20240902","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/107327480601300206","article-title":"Poorly differentiated and anaplastic thyroid cancer","volume":"13","author":"Patel","year":"2006","journal-title":"Cancer Control"},{"key":"R9-3-20240902","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1002\/1097-0142(20010615)91:12<2335::AID-CNCR1266>3.0.CO;2-1","article-title":"Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival","volume":"91","author":"Haigh","year":"2001","journal-title":"Cancer"},{"key":"R10-3-20240902","first-page":"83","article-title":"Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy","volume":"18","author":"Junor","year":"1992","journal-title":"Eur J Surg Oncol"},{"key":"R11-3-20240902","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1067\/msy.2002.119936","article-title":"The important role of operations in the management of anaplastic thyroid carcinoma","volume":"131","author":"Sugino","year":"2002","journal-title":"Surgery"},{"key":"R12-3-20240902","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1053\/ejso.2000.1098","article-title":"Effect of primary treatment on survival in anaplastic thyroid carcinoma","volume":"27","author":"Besic","year":"2001","journal-title":"Eur J Surg Oncol"},{"key":"R13-3-20240902","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1200\/JCO.2008.16.3279","article-title":"Phase II trial of sorafenib in advanced thyroid cancer","volume":"26","author":"Gupta-Abramson","year":"2008","journal-title":"J Clin Oncol"},{"key":"R14-3-20240902","first-page":"1167","article-title":"Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in the treatment of advanced thyroid cancer: A meta-analysis of randomized controlled trials","volume":"9","author":"Yimaer","year":"2016","journal-title":"Onco Targets Ther"},{"key":"R15-3-20240902","first-page":"3408","article-title":"A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer","volume":"62","author":"Dowlati","year":"2002","journal-title":"Cancer Res"},{"key":"R16-3-20240902","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"R17-3-20240902","doi-asserted-by":"crossref","first-page":"973820","DOI":"10.1155\/2012\/973820","article-title":"Prostate-specific membrane antigen-based therapeutics","volume":"2012","author":"Akhtar","year":"2012","journal-title":"Adv Urol"},{"key":"R18-3-20240902","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.1038\/s41598-017-05481-z","article-title":"PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics","volume":"7","author":"Bychkov","year":"2017","journal-title":"Sci Rep"},{"key":"R19-3-20240902","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00259-017-3904-0","article-title":"Anaplastic thyroid carcinoma on 68 Ga-PSMA PET\/CT: Opening new frontiers","volume":"45","author":"Damle","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R20-3-20240902","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s13139-016-0408-y","article-title":"Unusual uptake of prostate specific tracer 68Ga-PSMA-HBED-CC in a benign thyroid nodule","volume":"50","author":"Damle","year":"2016","journal-title":"Nucl Med Mol Imaging"},{"key":"R21-3-20240902","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/RLU.0000000000002010","article-title":"Recurrent medullary thyroid carcinoma on 68Ga-prostate-specific membrane antigen PET\/CT: Exploring new theranostic avenues","volume":"43","author":"Arora","year":"2018","journal-title":"Clin Nucl Med"},{"key":"R22-3-20240902","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1097\/RLU.0000000000001148","article-title":"PSMA expression in papillary thyroid carcinoma: Opening a new horizon in management of thyroid cancer?","volume":"41","author":"Taywade","year":"2016","journal-title":"Clin Nucl Med"},{"key":"R23-3-20240902","first-page":"3192","article-title":"Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature","volume":"59","author":"Chang","year":"1999","journal-title":"Cancer Res"},{"key":"R24-3-20240902","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00259-017-3922-y","article-title":"Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives","volume":"45","author":"Backhaus","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R25-3-20240902","doi-asserted-by":"crossref","first-page":"856189","DOI":"10.1155\/2013\/856189","article-title":"The role of fluorine-18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: An overview","volume":"2013","author":"Treglia","year":"2013","journal-title":"Int J Endocrinol"},{"key":"R26-3-20240902","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/RLU.0000000000002942","article-title":"Posttherapeutic critical organ dosimetry of extensive 177Lu-PSMA inhibitor therapy with metastatic castration-resistant prostate cancer: One center results","volume":"45","author":"\u00d6zkan","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R27-3-20240902","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/RLU.0000000000002806","article-title":"68Ga-prostate-specific membrane antigen-11 PET\/CT: A new imaging option for recurrent glioblastoma multiforme?","volume":"45","author":"Kunikowska","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R28-3-20240902","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/RLU.0000000000002833","article-title":"Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients","volume":"45","author":"Yadav","year":"2020","journal-title":"Clin Nucl Med"},{"key":"R29-3-20240902","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-018-4717-y","article-title":"Prostate-specific membrane antigen in breast cancer: A comprehensive evaluation of expression and a case report of radionuclide therapy","volume":"169","author":"Tolkach","year":"2018","journal-title":"Breast Cancer Res Treat"}],"container-title":["Indian Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.4103\/ijnm.ijnm_21_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T07:37:22Z","timestamp":1779694642000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijnm.co.in\/ga-68-prostate-specific-membrane-antigen-hbed-cc-positron-emission-tomography-computed-tomography-in-anaplastic-thyroid-carcinoma\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijnm.ijnm_21_22","relation":{},"ISSN":["0972-3919"],"issn-type":[{"value":"0972-3919","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}